Godavari Biorefineries Limited – Investor Presentation Summary

Key Operational Highlights

  • Commenced operations at a new 200 KLPD dual-feedstock (corn/grain-based) distillery at Sameerwadi, Karnataka.
  • The new facility adds 60 million litres of annual ethanol capacity, taking GBL's total capacity to 800 KLPD.
  • The distillery allows smoother transitions between raw materials based on seasonal availability.

Key drivers of operational performance: Feedstock diversification strategy enhancing supply chain resilience.

Segment-wise Performance

Performance by segment was not explicitly broken down in the provided data.

Financial Highlights

Revenue from Operations: Rs. 557.9 Cr (Q1 FY27) vs Rs. 533.2 Cr (Q1 FY26); 4.6% YoY growth.

Total Income: Rs. 559.9 Cr (Q1 FY27) vs Rs. 534.0 Cr (Q1 FY26); 4.9% YoY growth.

EBITDA: Rs. 2.6 Cr (Q1 FY27) vs Rs. 6.5 Cr (Q1 FY26); (60.5%) YoY decline.

PAT: Rs. (19.3) Cr (Q1 FY27) vs Rs. (16.0) Cr (Q1 FY26).

EPS: Not Specified.

Margins: EBITDA Margin: 0.5% (Q1 FY27) vs 1.2% (Q1 FY26); PAT Margin: (3.5%) (Q1 FY27) vs (3.0%) (Q1 FY26).

YoY/QoQ comparison: Q1 FY27 vs Q1 FY26 provided.

Drivers of financial performance: Not explicitly stated beyond the operational update.

Comparison to market estimates: Not Provided.

Key Risks: Mentioned risks include performance of the Indian and global economies, industry performance, competition, the company's ability to implement its strategy, growth and expansion, technological changes, and market risks.

Geographical Revenue Split

Domestic vs Export/Regional Revenue: Not Specified.

Balance Sheet Snapshot

Net Debt/Equity: Not Specified.

Reserves: Not Specified.

Current Assets/Liabilities: Not Specified.

Working Capital/Leverage Metrics: Not Specified.

Financial Health Insights: Not Specified.

Capex & Cash Flow Health

Capital Expenditure: Not Specified for the period.

Free Cash Flow: Not Specified.

Operating Cash Flow: Not Specified.

Net Debt Movement: Not Specified.

Investment Rationale: Expanding capacity and building a more adaptable bio-based manufacturing system.

Strategic & R&D Initiatives

Investments in Innovation:

  • Drug Discovery: Lead anti-cancer molecule MSP008-22 (first-in-class oral small molecule inhibitor for Triple-Negative Breast Cancer) developed by Sathgen Therapeutics. Clinical Study Report for safety trials submitted; application filed with CDSCO for next trial phase (preliminary efficacy).
  • Bio-Butanol: Exploring production through global partnerships (e.g., Synthomer, Catalyxx) as a next-generation diesel-blending fuel.
  • DME (Dimethyl Ether): Pilot-scale validation project in collaboration with ICT for conversion of CO₂ and hydrogen; trials expected to conclude by Q4 FY27.

Expected impact on growth: For MSP008-22, preliminary trial results expected Q2 FY28; full trial completion estimated by Q2 2030.

Strategic Rationale: Building a stronger, more adaptable bio-based manufacturing system; positioning at the heart of the shift from fossil-based to bio-based solutions.

Industry Trends & Business Environment

Macro/Industry Trends: Geopolitical uncertainties and crude oil supply volatility reinforcing the role of domestic ethanol; policy discussions expanding towards higher ethanol blends (Beyond E20) and flex-fuel vehicles; industry adoption of multiple feedstock pathways.

Impact on Company: Market demand for dependable, integrated bio-based partners is increasing, which aligns with GBL's integrated biorefinery model.

Management Commentary & Growth Outlook

Strategic Outlook: "Everything we do begins with the sun, the soil, and the small farmer."

FY Guidance: Exploring increasing corn/grain capacity to a dual and fungible 360 KLPD within the existing 800 KLPD limit to mitigate climate risks and enhance resilience.

Market Share Targets: Not Specified.

Risks and Opportunities: Highlighted global supply tightness making GBL's ethanol a preferred source for export customers.

Additional Updates

Awards & Recognition:

  • Winner – Bioenergy Producer at the 5th India Green Energy Awards 2025.
  • Responsible Care Certification renewal confirmed at ICC Lognext 2026.

Representation:

  • Dr. Sangeeta Srivastava spoke at Bio Innovations APAC 2026, Singapore.
  • Company represented in a US trade delegation.